Esperion Therapeutics, Inc. (ESPR)
Automate Your Wheel Strategy on ESPR
With Tiblio's Option Bot, you can configure your own wheel strategy including ESPR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ESPR
- Rev/Share 1.3235
- Book/Share -2.1731
- PB -0.3773
- Debt/Equity -0.6987
- CurrentRatio 1.1765
- ROIC -0.3615
- MktCap 162503360.0
- FreeCF/Share -0.5117
- PFCF -1.6193
- PE -1.0495
- Debt/Assets 0.919
- DivYield 0
- ROE 0.4007
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ESPR | Goldman | -- | Neutral | -- | $4 | Dec. 18, 2024 |
| Initiation | ESPR | Cantor Fitzgerald | -- | Overweight | -- | $8 | Dec. 17, 2024 |
News
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs' Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Micro Labs has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, …
Read More
Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET.
Read More
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease – ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with HLS Therapeutics (TSX:HLS) for the exclusive rights to commercialize NEXLETOL* and NEXLIZET* in Canada.
Read More
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year.
Read More
Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Officer Betty Jean Swartz - Chief Business Officer Conference Call Participants Dennis Ding - Jefferies Joseph Pantginis - H.C. Wainwright Jason Zemansky - Bank of America Kristen Kluska - Cantor Fitzgerald Jessica Fye - J.P.
Read More
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.34 per share a year ago.
Read More
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates.
Read More
Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025.
Read More
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
ANN ARBOR, Mich., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 11, 2025, the Company granted ten new employees 58,300 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.
Read More
About Esperion Therapeutics, Inc. (ESPR)
- IPO Date 2013-06-26
- Website https://www.esperion.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Sheldon L. Koenig
- Employees 304